PELP1 oncogenic functions involve CARM1 regulation

Carcinogenesis

Volumn 34, Issue 7, 2013, Pages 1468-1475

  Mann, Monica ^a   Cortez, Valerie ^a   Vadlamudi, Ratna ^a,b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b San Antonio Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; COACTIVATOR ASSOCIATED ARGININE METHYLTRANSFERASE 1; ESTROGEN RECEPTOR ALPHA; LYSINE; METHYLTRANSFERASE; ONCOPROTEIN; PROLINE GLUTAMIC ACID AND LEUCINE RICH PROTEIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION;

ANIMALS; ARGININE; BREAST NEOPLASMS; CHROMATIN IMMUNOPRECIPITATION; CO-REPRESSOR PROTEINS; ENZYME INHIBITORS; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; METHYLATION; MICE; PROMOTER REGIONS, GENETIC; PROTEIN INTERACTION MAPPING; PROTEIN-ARGININE N-METHYLTRANSFERASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880317205     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt091     Document Type: Article

References (25)

1. Pathiraja, T.N. et al. (2010) Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response. J. Mammary Gland Biol. Neoplasia, 15, 35-47.
2. Le Romancer, M. et al. (2011) Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr. Rev., 32, 597-622.
3. Jovanovic, J. et al. (2010) The epigenetics of breast cancer. Mol. Oncol., 4, 242-254.
4. Bedford, M.T. et al. (2009) Protein arginine methylation in mammals: who, what, and why. Mol. Cell, 33, 1-13.
5. Lan, F. et al. (2009) Epigenetic regulation: methylation of histone and nonhistone proteins. Sci. China C Life Sci., 52, 311-322.
6. Bannister, A.J. et al. (2011) Regulation of chromatin by histone modifications. Cell Res., 21, 381-395.
7. O'Brien, K. et al. (2010) CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development, 137, 2147-2156.
8. Chakravarty, D. et al. (2010) PELP1: a novel therapeutic target for hormonal cancers. IUBMB Life, 62, 162-169.
9. Vadlamudi, R.K. et al. (2001) Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J. Biol. Chem., 276, 38272-38279.
10. Mann, M. et al. (2011) Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers, 3, 1691-1707.
11. Vallabhaneni, S. et al. (2011) Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res. Treat., 130, 377-385.
12. Nair, S.S. et al. (2004) Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res., 64, 6416-6423.
13. Nair, S.S. et al. (2010) PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep., 11, 438-444.
14. Nair, B.C. et al. (2010) Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res., 70,7166-7175.
15. Rajhans, R. et al. (2007) Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res., 67, 5505-5512.
16. Chakravarty, D. et al. (2010) Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res., 70, 4092-4101.
17. Wysocka, J. (2006) Identifying novel proteins recognizing histone modifications using peptide pull-down assay. Methods, 40, 339-343.
18. Cortez, V. et al. (2012) Targeting PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res., 14, R108.
19. Phillips, T. et al. (2007) Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl. Immunohistochem. Mol. Morphol., 15, 325-331.
20. Bock, I. et al. (2011) Application of Celluspots peptide arrays for the analysis of the binding specificity of epigenetic reading domains to modified histone tails. BMC Biochem., 12, 1471-2091.
21. Chen, D. et al. (1999) Regulation of transcription by a protein methyltransferase. Science, 284, 2174-2177.
22. Habashy, H.O. et al. (2010) The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminallike subtype. Breast Cancer Res. Treat., 120, 603-612.
23. El Messaoudi, S. et al. (2006) Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc. Natl Acad. Sci. U.S.A., 103, 13351-13356.
24. Frietze, S. et al. (2008) CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res., 68, 301-306.
25. Al-Dhaheri, M. et al. (2011) CARM1 is an important determinant of ERα- dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res., 71, 2118-2128.